RANIT SYRUP

Product Category: Histamine H2 Receptor Antagonist

Composition: RANITIDINE ORAL SOLUTION IP (75 MG/5 ML)

Therapeutic Category: Gastric Acid Reducer

Mechanism of Action: Ranitidine, an H2 receptor antagonist, competitively inhibits histamine at the histamine H2 receptors of the gastric parietal cells. This results in a reduction of gastric acid secretion, making it effective in the treatment of conditions related to excess stomach acid.

Indications:

Dosage:

Adult (12 years and older):

The standard dosage regimen for duodenal or benign gastric ulcer is 150 mg (10 mL, i.e. 2 teaspoonful) twice daily or 300 mg (20 mL) once nightly. In most cases of duodenal ulcer, benign gastric ulcer and post-operative ulcer, healing occurs within 4 weeks. Healing usually occurs after a further 4 weeks in those not fully healed after the initial 4 weeks.

For the prevention of non-steroidal anti-inflammatory drug associated duodenal ulcers, 150 mg (10 mL) twice daily may be given concomitantly with non-steroidal anti-inflammatory drug therapy.

In the management of reflux oesophagitis, the usual course of treatment is either 150 mg (10 mL) twice daily or 300 mg (20 mL) once nightly administered for up to a period of eight weeks or if necessary 12 weeks. In patients with moderate to severe oesophagitis the dosage may be increased to 150 mg (10 mL) four times daily; if necessary. For the long-term management of reflux oesophagitis, the recommended adult oral dose is 150 mg (10 mL) twice daily for the prevention of relapse in patients with reflux oesophagitis.

In patients with Zollinger-Ellison syndrome the starting dose is 150 mg (10 mL) three times daily that can be increased to 6 grams daily.

Children (3 to 11 years): As directed by registered healthcare professional.

Pack Size: Available in 60 mL amber coloured PET Bottle.